Hybrid promoters for muscle expression
Hybrid promoters combining liver-selective enhancers with muscle-selective promoters enhance transgene expression in muscle cells, addressing size constraints and immune response issues in gene therapy, offering a potent tool for neuromuscular disorder treatments.
Patent Information
- Application Number
- JP2024135741
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2019-04-08
- Filing Date
- 2024-08-15
- Publication Date
- 2024-11-08
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing gene therapy methods face challenges in achieving strong transgene expression in target tissues while minimizing vector toxicity and immune response, particularly due to size constraints of vectors like AAV, which limit the inclusion of promoter-enhancer combinations.
Development of hybrid promoters combining liver-selective enhancers with muscle-selective promoters, such as HS-CRM8 with spC5.12, to enhance transgene expression in muscle cells, while maintaining vector size compatibility.
The hybrid promoters significantly increase transgene expression in muscle cells, achieving up to 150-fold enhancement without significant leakage into non-muscle tissues, providing a robust tool for neuromuscular disorder therapies.
Smart Images

Figure 2024159800000023 
Figure 2024159800000024 
Figure 2024159800000025
Abstract
Description
[Technical field]
[0001] The present invention relates to hybrid promoters for driving gene expression in muscle. The present invention further relates to expression cassettes and vectors containing said hybrid promoters. Methods of implementing these hybrid promoters, in particular methods of gene therapy, are also disclosed herein. [Background technology]
[0002] Neuromuscular disorders represent one of the major challenges for in vivo-based gene therapy.However, poor transgene expression in desired target tissues and anti-transgene immunity remain major hurdles in achieving successful gene therapy for many diseases.Therefore, there is still a need to provide strong expression of transgene in target cells, but with low doses of vector, to prevent both potential toxicity of vector and immune response against vector. [Prior art documents] [Patent documents]
[0003] [Patent Document 1] Patent application EP17306448.6 [Patent Document 2] Patent application EP17306447.8 [Patent Document 3] EP18305399 [Patent Document 4] WO2005 / 118792 [Patent Document 5] Application PCT / 2017 / 072942 [Patent Document 6] Application PCT / EP2017 / 072945 [Patent Document 7] Application PCT / EP2017 / 072944 [Patent Document 8] EP18306088 [Patent Document 9] WO2018162748 [Patent Document 10] WO2018046772 [Patent Document 11] WO2018046774 [Patent Document 12] WO2018046775 [Patent Document 13] WO2015158924 [Non-patent literature]
[0004] [Non-Patent Document 1] Carrieri et al., 2012, Nature 491: 454-7 [Non-Patent Document 2] Zucchelli et al., 2015, RNA Biol, 12(8):771-9 [Non-Patent Document 3] Indrieri et al., 2016, Sci Rep, 6: 27315 [Non-Patent Document 4] Chuah et al., Molecular Therapy, 2014, Vol. 22, No. 9, p. 1605 [Non-Patent Document 5] Wang et al., Gene Therapy, 15, 1489-1499 (2008) [Non-Patent Document 6] Ling et al., July 18, 2016, Hum Gene Ther Methods. [Non-Patent Document 7] Vercauteren et al., 2016, Mol. Ther., vol. 24(6), pp. 1042 [Non-Patent Document 8] Rosario et al., 2016, Mol Ther Methods Clin Dev. 3, page 16026 [Non-Patent Document 9] McCarty et al., Gene Therapy, 2003 [Non-Patent Document 10] Wu Z. et al., Mol Ther., 2010, Vol. 18(1): 80-86. [Non-Patent Document 11] Lai Y. et al., Mol Ther., 2010, Vol. 18(1): 75-79 [Non-Patent Document 12] Wang Y. et al., Hum Gene Ther Methods, 2012, Vol. 23(4): 225-33 [Non-Patent Document 13] "Remington's Pharmaceutical Sciences", E.W. Martin [Non-Patent Document 14] Chuah et al., Molecular Therapy, 2014, Vol. 22, No. 9, p. 1605 Summary of the Invention [Problem to be solved by the invention]
[0005] Theoretically, this goal can be addressed by selecting a promoter that provides strong expression in target cells. However, some problems may arise from their use. In particular, when designing constructs for gene therapy, one must be mindful of the size constraints specific to the vector used to deliver therapeutic transgenes. For example, the elements introduced into AAV vectors should have a smaller size due to the limitations presented by the maximum encapsidation size of AAV vectors, i.e., approximately 5 kb.
[0006] Here we describe the identification of enhancer / promoter combinations that allow efficient expression of the protein muscle and have a size compatible with gene therapy vectors such as AAV vectors. [Means for solving the problem]
[0007] The present invention provides a genetic engineering strategy that implements novel hybrid promoters with muscle specificity. These hybrid promoters can be used for gene therapy of neuromuscular diseases. These novel hybrid promoters are based on the combination of one or more liver-selective enhancers operably linked to a muscle-selective promoter. Surprisingly, it is shown herein that the expression of transgenes is increased in muscle cells when placed under the control of such hybrid promoters that contain liver-selective enhancers.
[0008] Thus, a first aspect of the present invention relates to a nucleic acid molecule comprising one or more liver-selective enhancers operably linked to a muscle-selective promoter.
[0009] In further particular embodiments, the nucleic acid molecule comprises one liver-selective enhancer operably linked to the muscle-selective promoter. In another embodiment, the nucleic acid molecule comprises a plurality of liver-selective enhancers operably linked to the muscle-selective promoter. In a particular embodiment, the plurality of liver-selective enhancers comprises at least two liver-selective enhancers. In yet another embodiment, the plurality of liver-selective enhancers comprises two liver-selective enhancers. In a further embodiment, the plurality of liver-selective enhancers comprises three liver-selective enhancers. In a further embodiment, the plurality of liver-selective enhancers comprises four liver-selective enhancers. In yet another embodiment, the plurality of liver-selective enhancers comprises five liver-selective enhancers. In a particular embodiment, the nucleic acid molecule comprises one, two or three liver-selective enhancers, more particularly one or three liver-selective enhancers. In certain embodiments, all of the liver-selective enhancers of the plurality of liver-selective enhancers have the same sequence, and at least two of the liver-selective enhancers of the plurality of liver-selective enhancers have different sequences. In certain embodiments, all of the liver-selective enhancers of the plurality of liver-selective enhancers have the same sequence.
[0010] In a particular embodiment of the present invention of the nucleic acid of the present invention, the enhancer may be a short-sized liver-selective enhancer, or the multiple liver-selective enhancers may be multiple short-sized liver-selective enhancers. In particular, the liver-selective enhancer for use in the present invention may consist of 10 to 175 nucleotides, for example 40 to 100 nucleotides, in particular 50 to 80 nucleotides. In a particular embodiment, the liver-selective enhancer for use in the present invention may consist of 70 to 75 nucleotides. In a particular embodiment, the liver-selective enhancer is the 72 nucleotide HS-CRM8 enhancer consisting of SEQ ID NO: 1, or a functional fragment of SEQ ID NO: 1 having liver-selective enhancer activity. In another embodiment, the liver-selective enhancer is a functional variant of the 72 nucleotide HS-CRM8 enhancer that is at least 80% identical to SEQ ID NO: 1, such as at least 85% identical, particularly at least 90% identical, more particularly at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or even at least 99% identical to SEQ ID NO: 1, wherein said functional variant has liver-selective enhancer activity. In a further embodiment, the liver-selective enhancer is a functional fragment of a sequence that is at least 80% identical to SEQ ID NO: 1, such as at least 85% identical, particularly at least 90% identical, more particularly at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or even at least 99% identical to SEQ ID NO: 1, wherein said functional fragment has liver-selective enhancer activity.
[0011] Preferably, the promoter is a short size muscle-selective promoter. In particular embodiments, the promoter is a CK6 promoter, a CK8 promoter, an Actal promoter, or a synthetic promoter C5.12 (spC5.12, alternatively referred to herein as "C5.12"). In particular embodiments, the muscle-selective promoter is an spC5.12 promoter. In further particular embodiments, the spC5-12 promoter is selected from: - a sequence consisting of SEQ ID NO: 2, 3 or 4, in particular the sequence as shown in SEQ ID NO: 2, or a functional fragment of SEQ ID NO: 2, 3 or 4, in particular SEQ ID NO: 2, wherein said fragment has muscle-selective promoter activity; - a sequence that is at least 80% identical, such as at least 85% identical, in particular at least 90% identical, more in particular at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or even at least 99% identical to any one of SEQ ID NOs: 2, 3 and 4, in particular SEQ ID NO: 2; and - a functional fragment of a sequence that is at least 80% identical, such as at least 85% identical, in particular at least 90% identical, more in particular a sequence that is at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or even at least 99% identical to any one of SEQ ID NO: 2, 3 and 4, in particular SEQ ID NO: 2, said functional fragment having muscle-selective promoter activity.
[0012] Optionally, the nucleic acid molecules described herein may further comprise an additional enhancer, for example a muscle-selective enhancer, for example the SA195 enhancer of SEQ ID NO: 34 or the MCK enhancer of SEQ ID NO: 5 or a functional variant thereof having a sequence at least 80% identical to SEQ ID NO: 34 or SEQ ID NO: 5, for example at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or even at least 99% identical to SEQ ID NO: 34 or SEQ ID NO: 5. In certain embodiments, the additional enhancer is located between the liver-selective enhancer or enhancers and the muscle-selective promoter. In certain embodiments, no additional enhancer is provided between the liver-selective enhancer or enhancers and the muscle-selective promoter.
[0013] The hybrid promoters of the present invention may be operably linked to a transgene of interest.Thus, the present invention further relates to an expression cassette comprising a nucleic acid molecule as described herein, operably linked to a transgene of interest.
[0014] The present invention further relates to a vector comprising the above expression cassette. In a particular embodiment, the vector is a plasmid vector. In another embodiment, the vector is a viral vector. Representative viral vectors include, without limitation, adenoviral vectors, retroviral vectors, lentiviral vectors and parvoviral vectors, such as AAV vectors. In a particular embodiment, the viral vector is an AAV vector, such as an AAV vector comprising AAV8 or AAV9 capsid.
[0015] The present invention also relates to an isolated recombinant cell comprising a nucleic acid construct according to the present invention.
[0016] The present invention further relates to a pharmaceutical composition comprising a pharma- ceutically acceptable carrier, a vector or an isolated cell of the invention.
[0017] Furthermore, the present invention also relates to an expression cassette, vector or cell as disclosed herein for use as a medicament. In this aspect, the transgene of interest contained in the expression cassette, vector or cell is a therapeutic transgene.
[0018] The present invention further relates to an expression cassette, a vector or a cell as disclosed herein for use in gene therapy.
[0019] In another aspect, the invention relates to an expression cassette, vector or cell as disclosed herein for use in treating a neuromuscular disorder. In particular, the neuromuscular disorder is a muscular dystrophy (e.g., myotonic dystrophy (Steiner's disease), Duchenne muscular dystrophy, Becker muscular dystrophy, limb-girdle muscular dystrophy, facioscapulohumeral muscular dystrophy, congenital muscular dystrophy, oculopharyngeal muscular dystrophy, distal muscular dystrophy, Emery-Dreifuss muscular dystrophy, motor neuron diseases (e.g., amyotrophic lateral sclerosis (ALS), spinal muscular atrophy ( Infantile progressive spinal muscular atrophy (type 1, Werdnig-Hoffmann disease), intermediate spinal muscular atrophy (type 2), juvenile spinal muscular atrophy (type 3, Kugelberg-Welander disease), adult spinal muscular atrophy (type 4), spinal-bulbar muscular atrophy (Kennedy disease), inflammatory myopathies (e.g., polymyositis, dermatomyositis, inclusion body myositis), diseases of the neuromuscular junction (e.g., myasthenia gravis, Lambert-Eaton (myasthenic) syndrome, congenital myasthenic syndrome), peripheral nerve The myopathy may be selected from the group consisting of myotonia congenita, myotonia congenita, myotonia congenita, myotonia nervosa ...
[0020] In a further particular embodiment, the disease is Coli disease and the transgene of interest is a GDE, for example a truncated form of a GDE. [Brief description of the drawings]
[0021] [Figure 1] FIG. 1 shows a schematic of promoter / enhancer association, with the size of each element indicated. [Diagram 2] Graph of mSeAP protein expression in muscle. C57BL / 6 mice were injected with 2x1011vg / mouse AAV9 vector expressing a murine secreted alkaline phosphatase (mSeAP) reporter gene under the transcriptional control of the spC5-12 promoter (spC5-12) or the same promoter fused with the MCK (MCK-spC5-12), H1 and MCK (H1-MCK-spC5-12), or H3 and MCK (H3-MCK-spC5-12) enhancers. Mice injected with PBS were used as control (PBS). One month after injection, mSeAP activity was measured in different muscles and the fold change compared to the levels measured in the PBS group is reported. Statistical analysis was performed by ANOVA (*=p<0.05, n=5 per group). [Diagram 3] Graph of mSEAP expression in non-muscle tissues. Liver, brain and kidney from C57BL / 6 mice treated as described in FIG. 2 were analyzed for mSEAP activity. Measured mSeAP activity is reported as fold change compared to levels measured in PBS-injected mice. Statistical analysis was performed by ANOVA (*=p<0.05, n=5 per group). [Figure 4]The presence of the MCK enhancer is not required to increase transgene expression in muscle. C57BL / 6 mice were injected with 4x1011vg / mouse of AAV9 vectors expressing a murine secreted alkaline phosphatase (mSeAP) reporter gene under the transcriptional control of the spC5-12 promoter (spC5-12), or the same promoter fused with the H3 (H3-spC5-12), or H3 and MCK (H3-MCK-spC5-12) enhancers. Mice injected with PBS were used as controls (PBS). One month after injection, mSeAP activity was measured in the heart, diaphragm, quadriceps, and triceps, and fold changes compared to the levels measured in the PBS group were reported. Statistical analysis was performed by ANOVA (n=4 per group, as indicated, *=p<0.05). [Diagram 5] The H3 enhancer increases muscle expression when fused to different muscle-specific promoters. C57BL / 6 mice were injected with 5x1011vg / mouse of AAV9 vectors expressing the murine secreted alkaline phosphatase (mSeAP) reporter gene under the transcriptional control of the CK6 or CK8 promoters, or enhancer-promoter combinations consisting of the H3 enhancer fused to CK6 (H3-CK6) or the H3 enhancer fused to CK8 (H3-CK8). Mice injected with PBS were used as controls (PBS). 15 days after vector injection, mSeAP activity was measured in the heart, quadriceps, and triceps, and fold changes were reported compared to the levels measured in mice injected with mSeAP under the control of the CK6 promoter. Statistical analysis was performed by ANOVA (n=4 per group, as indicated, *=p<0.05). [Figure 6]The H3 enhancer increases muscle expression when fused to the ACTA1 muscle-specific promoter. C57BL / 6 mice were injected with 4x1011vg / mouse of an AAV9 vector expressing a murine secreted alkaline phosphatase (mSeAP) reporter gene under the transcriptional control of enhancer-promoter combinations consisting of the H3 enhancer fused to spC5-12 (H3-spC5-12) or the H3 enhancer fused to the Acta1 promoter (H3-Acta1). Mice injected with PBS were used as controls (PBS). One month after injection, mSeAP activity was measured in the heart, diaphragm, quadriceps, and triceps, and fold changes compared to levels measured in the PBS group were reported. Statistical analysis was performed by ANOVA (*=p<0.05 vs. PBS, n=4 per group). [Figure 7] The F enhancer increases muscle expression when fused to a muscle-specific promoter. C57BL / 6 mice were injected with 4 × 1011 vg / mouse of AAV9 vectors expressing a murine secreted alkaline phosphatase (mSeAP) reporter gene under the transcriptional control of the spC5-12 promoter or the combination of the F enhancer and spC5-12 promoter (F-spC5-12). Mice injected with PBS were used as controls (PBS). 15 days after vector injection, mSeAP activity was measured in the quadriceps muscle and the fold change compared to the levels measured in the PBS group was reported. Statistical analysis was performed by ANOVA (* = p < 0.05 vs. spC5-12, n = 3–4 per group). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0022] definition In the context of the present invention, a "transcriptional regulatory element" is a DNA sequence that is capable of driving or enhancing expression of a transgene in a tissue or cell.
[0023] In the context of the present invention, the expression "muscle-selective promoter" includes natural or synthetic muscle-selective promoters. Additionally, the expression "liver-selective enhancer" includes natural or synthetic liver-selective enhancers.
[0024] According to the present invention, tissue selectivity means that a transcriptional regulatory element preferentially promotes (in the case of a promoter) or enhances (in the case of an enhancer) the expression of a gene operably linked to said transcriptional regulatory element in a given tissue or set of tissues compared to expression in another tissue. This definition of "tissue selectivity" does not exclude the possibility that a tissue-selective transcriptional regulatory element (e.g., a muscle-selective promoter) may leak to some extent. "Leaking", "leaking" or deviations therefrom refer to the possibility that a muscle-selective promoter may promote or increase the expression of a transgene operably linked to said promoter in another tissue, albeit at a lower expression level. For example, a muscle-selective promoter may leak in liver tissue, meaning that the expression driven by this promoter is higher in muscle tissue than in liver tissue. Alternatively, a tissue-selective transcriptional regulatory element may be a "tissue-specific" transcriptional regulatory element, meaning that not only does the transcriptional regulatory element promote or enhance expression in a given tissue or set of tissues in a preferential manner, but that the regulatory element does not promote or enhance expression in other tissues, or only slightly.
[0025] According to the present invention, a "transgene of interest" refers to a polynucleotide sequence that encodes an RNA or protein product and that can be introduced into a cell for the purpose sought and expressed under appropriate conditions. A transgene of interest can encode a product of interest, for example a therapeutic or diagnostic product of interest. A "therapeutic transgene" is selected and used to achieve expression of said therapeutic transgene in cells, tissues or organs where expression of said therapeutic transgene is required, in particular to bring about a desired therapeutic outcome. Therapy can be achieved in several ways, including by expressing a protein in cells that do not express said protein, by expressing a protein in cells that express a mutant form of the protein, by expressing a protein that is toxic to the target cells in which the protein is expressed (e.g. a strategy used to kill unwanted cells such as cancer cells), by expressing an antisense RNA that induces gene suppression or exon skipping, or by expressing a silencing RNA, such as an shRNA, whose purpose is to suppress the expression of a protein. The transgene of interest can also encode a nuclease for targeted genome engineering, such as a CRISPR-associated protein 9 (Cas9) endonuclease, a meganuclease, or a transcription activator-like effector nuclease (TALEN). The transgene of interest can also be a guide RNA or a series of guide RNAs for use with the CRISPR / Cas9 system, or a correction matrix for use in targeted genome engineering strategies with nucleases as previously described. Other transgenes of interest include, without limitation, synthetic long non-coding RNAs (SINEUP; Carrieri et al., 2012, Nature 491:454-7; Zucchelli et al., 2015, RNA Biol, 12(8):771-9; Indrieri et al., 2016, Sci Rep, 6:27315) and artificial microRNAs. Other specific transgenes of interest useful in the practice of the present invention are described below.
[0026] According to the present invention, the term "treatment" includes curative, alleviating or preventative effects. Thus, therapeutic and prophylactic treatments include ameliorating symptoms of a disorder or preventing or otherwise reducing the risk of developing a particular disorder. Treatments can be administered to delay, slow or reverse the progression of a disease and / or one or more of its symptoms. The term "prophylactic" can be considered to reduce the severity or onset of a particular condition. "Prophylactic" also includes preventing the recurrence of a particular condition in a patient previously diagnosed with that condition. "Therapeutic" can also refer to the reduction in the severity of an existing condition. The term "treatment" is used herein to refer to any regimen that an animal, particularly a mammal, more particularly a human subject, can benefit from. In certain embodiments, the mammal may be an infant or adult subject, such as a human infant or a human adult.
[0027] By "cell of therapeutic interest" or "tissue of therapeutic interest" herein is meant the primary cell or tissue in which expression of a therapeutic transgene is useful for the treatment of a disorder. In the present invention, the tissue of interest is muscle tissue.
[0028] Hybrid Promoter The inventors of the present invention have designed transcriptional regulatory elements, also referred to herein as "hybrid promoters," to increase the efficacy of gene therapy while fitting within the size constraints of gene therapy vectors, e.g., the size constraints of AAV vectors.
[0029] The nucleic acid molecules of the invention comprise (i) one or more liver-selective enhancers operably linked to (ii) a muscle-selective promoter.
[0030] The liver-selective enhancer or the liver-selective enhancers can be selected from liver-selective enhancers known to those skilled in the art. In a particular embodiment, the nucleic acid molecule of the present invention comprises one and only one liver-selective enhancer. In this embodiment, the size of the liver-selective enhancer may be 10-500 nucleotides, for example 10-175 nucleotides, particularly 40-100 nucleotides, particularly 50-80 nucleotides, more particularly 70-75 nucleotides. In another embodiment, when multiple liver-selective enhancers are introduced, the size of the combination of the multiple liver-selective enhancers may be 10-500 nucleotides, for example 40-400 nucleotides, particularly 70-250 nucleotides. In a particular embodiment, the liver-selective enhancer is a naturally occurring enhancer located in cis of a gene selectively expressed in hepatocytes. In a further particular embodiment, the liver-selective enhancer may be an artificial liver-selective enhancer. Exemplary artificial liver-selective enhancers useful in the practice of the present invention include, without limitation, those disclosed in Chuah et al., Molecule Therapy, 2014, Vol. 22, No. 9, p. 1605, in particular HS-CRM1 (SEQ ID NO:21), HS-CRM2 (SEQ ID NO:22), HS-CRM3 (SEQ ID NO:23), HS-CRM4 (SEQ ID NO:24), HS-CRM5 (SEQ ID NO:25), HS-CRM6 (SEQ ID NO:26), HS-CRM7 (SEQ ID NO:27), HS-CRM8 (SEQ ID NO:1), HS-CRM9 (SEQ ID NO:28), HS-CRM10 (SEQ ID NO:29), HS-CRM11 (SEQ ID NO:30), HS-CRM12 (SEQ ID NO:31), HS-CRM13 (SEQ ID NO:32), and HS-CRM14 (SEQ ID NO:33). In certain embodiments, the liver-selective enhancer may be selected in the group consisting of HS-CRM1, HS-CRM2, HS-CRM3, HS-CRM5, HS-CRM6, HS-CRM7, HS-CRM8, HS-CRM9, HS-CRM10, HS-CRM11, HS-CRM13 and HS-CRM14. In further particular embodiments, the liver-selective enhancer may be selected in the group consisting of HS-CRM2, HS-CRM7, HS-CRM8, HS-CRM11, HS-CRM13 and HS-CRM14.In a particular embodiment, the liver-selective enhancer is the HS-CRM8 enhancer consisting of SEQ ID NO: 1, or a functional fragment of SEQ ID NO: 1 having liver-selective enhancer activity. In another embodiment, the liver-selective enhancer is a functional variant of the HS-CRM8 enhancer that is at least 80% identical to SEQ ID NO: 1, such as at least 85% identical, particularly at least 90% identical, more particularly at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or even at least 99% identical to SEQ ID NO: 1, wherein said functional variant has liver-selective enhancer activity. In a further embodiment, the liver-selective enhancer is a functional fragment of a sequence that is at least 80% identical to SEQ ID NO: 1, such as at least 85% identical, particularly at least 90% identical, more particularly at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or even at least 99% identical to SEQ ID NO: 1, said functional fragment having liver-selective enhancer activity. In the case of multiple liver-selective enhancers, said enhancers may be directly fused or separated by a linker. Direct fusion means that the first nucleotide of an enhancer immediately follows the last nucleotide of the upstream enhancer. In the case of linking via a linker, a nucleotide sequence is present between the last nucleotide of the upstream enhancer and the first nucleotide of the subsequent downstream enhancer. For example, the length of the linker may be comprised between 1 to 50 nucleotides, such as 1 to 40 nucleotides, such as 1 to 30 nucleotides, such as 1 to 20 nucleotides, such as 1 to 10 nucleotides. In the present invention, the design of the nucleic acid molecule can take into account the size constraints mentioned above, and therefore such linkers, if any, are preferably short. Exemplary short linkers include nucleic acid sequences consisting of linkers of less than 15 nucleotides, in particular less than 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3 or less than 2 nucleotides, for example 1 nucleotide.
[0031] The second transcriptional regulatory element present in the nucleic acid molecule of the present invention is a muscle-selective promoter, for example, a natural or synthetic muscle-selective promoter. The muscle-selective promoter is a short-size muscle-selective promoter. In the context of the present invention, a "short-size promoter" has a length of 2600 nucleotides or less, particularly 2000 nucleotides or less, and has muscle-selective promoter activity when operably linked to a transgene. In certain embodiments, the muscle-selective promoter has a length of 1500 nucleotides or less, 1100 nucleotides or less, 600 nucleotides or less, 500 nucleotides or less, 400 nucleotides or less, 300 nucleotides or less, or 200 nucleotides or less. Exemplary muscle promoters useful in the practice of the present invention include, without limitation, CK6 promoter (SEQ ID NO: 6), CK8 promoter (SEQ ID NO: 7), Actal promoter (SEQ ID NO: 8) or synthetic promoter C5.12. In a particular embodiment, the muscle-selective promoter is a synthetic promoter C5.12 (spC5.12, alternatively referred to herein as "C5.12"), such as the spC5.12 shown in SEQ ID NO: 2, 3 or 4 or the spC5.12 promoter disclosed in Wang et al., Gene Therapy, vol. 15, pp. 1489-1499 (2008). The present invention also allows for the introduction of functional fragments and functional variants of muscle-selective promoters. In particular, muscle-selective promoters useful in the practice of the present invention can be selected from, without limitation, the following: - a sequence as depicted in SEQ ID NO: 2, 3, 4, 6, 7 or 8, in particular SEQ ID NO: 2, 3 or 4, more particularly consisting of the sequence as depicted in SEQ ID NO: 2, or a functional fragment of SEQ ID NO: 2, 3, 4, 6, 7 or 8, in particular SEQ ID NO: 2, 3 or 4, more particularly SEQ ID NO: 2, said fragment having muscle-selective promoter activity; - a sequence that is at least 80% identical, such as at least 85% identical, in particular at least 90% identical, more in particular at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or even at least 99% identical to any one of SEQ ID NOs: 2, 3, 4, 6, 7 or 8, in particular to any one of SEQ ID NOs: 2, 3 and 4, in particular to SEQ ID NO: 2; and - a functional fragment of a sequence at least 80% identical, such as at least 85% identical, in particular at least 90% identical, more particularly at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or even at least 99% identical to any one of SEQ ID NOs: 2, 3, 4, 6, 7 or 8, in particular any one of SEQ ID NOs: 2, 3 and 4, more particularly at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or even at least 99% identical to SEQ ID NO: 2, said functional fragment having muscle-selective promoter activity. Other muscle-selective promoters include, without limitation, MCK promoter (SEQ ID NO: 14), desmin promoter (SEQ ID NO: 15) and unc45b promoter (SEQ ID NO: 16), or functional fragments thereof having muscle-selective promoter activity. In a further embodiment, the sequence of the muscle-selective promoter consists of a sequence that is at least 80% identical, such as at least 85% identical, in particular at least 90% identical, more particularly at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or even at least 99% identical to any one of SEQ ID NOs: 14, 15 or 16. In another embodiment, the muscle-selective promoter is a functional fragment of a sequence that is at least 80% identical, such as at least 85% identical, in particular at least 90% identical, more particularly at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or even at least 99% identical to any one of SEQ ID NOs: 14, 15 or 16, wherein said functional fragment has muscle-selective promoter activity.
[0032] In addition, but optionally, the nucleic acid molecules described herein may further comprise an additional enhancer, for example a muscle-selective enhancer, for example the MCK enhancer of SEQ ID NO: 5 or a functional variant thereof having a sequence at least 80% identical to SEQ ID NO: 5, for example at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or even at least 99% identical to SEQ ID NO: 5. In certain embodiments, the additional enhancer, in particular the MCK enhancer of SEQ ID NO: 5 or a functional variant thereof, is located between the liver-selective enhancer or liver-selective enhancers and the muscle-selective promoter.
[0033] In the context of the present invention, the transcriptional regulatory elements introduced into the nucleic acid molecule of the present invention (i.e. (i) the liver-selective enhancer or enhancers; (ii) any other enhancers described in the preceding paragraph; and (iii) the muscle-selective promoter) may be directly fused or linked via a linker. For example, in the case of a design with one liver-selective enhancer and a muscle-selective promoter, direct fusion means that the first nucleotide of the promoter immediately follows the last nucleotide of the liver-selective enhancer. Additionally, in the case of a design with multiple liver-selective enhancers and muscle-selective promoters, direct fusion means that the first nucleotide of the promoter immediately follows the last nucleotide of the 3'-most liver-selective enhancer. When linked via a linker, the nucleotide sequence is between the last nucleotide of the only liver-selective enhancer and the first nucleotide of the promoter, or between the last nucleotide of the 3'-most liver-selective enhancer and the first nucleotide of the promoter. For example, the length of the linker may be between 1 and 1500 nucleotides, for example, 1 to 1000 nucleotides (for example, 101, 300, 500 or 1000 nucleotides, for example, the linkers shown in SEQ ID NOs: 17, 18, 19 and 20, respectively), for example, 1 to 500 nucleotides, for example, 1 to 300 nucleotides, for example, 1 to 100 nucleotides, for example, 1 to 50 nucleotides, for example, 1 to 40 nucleotides, for example, 1 to 30 nucleotides, for example, 1 to 20 nucleotides, for example, 1 to 10 nucleotides. In the present invention, the design of the core molecule can take into account the size constraints mentioned above, and therefore, such linkers, if any, are preferably short. Representative short linkers include nucleic acid sequences consisting of less than 15 nucleotides, in particular less than 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3 nucleotides or less than 2 nucleotides, for example, linkers of 1 nucleotide.
[0034] In certain embodiments, a nucleic acid molecule of the invention comprises, specifically from 5' to 3' in this order: - one selective liver-selective, specifically HS-CRM8 enhancer, or its functionality or a functional fragment; and a muscle-selective promoter, in particular the spC5.12 promoter or a functional variant or functional fragment thereof.
[0035] According to a particular variant of this embodiment, the nucleic acid molecule of the invention consists of a sequence as shown in SEQ ID NO:9 or a functional variant thereof having a sequence at least 80% identical to SEQ ID NO:9, e.g. at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or even at least 99% identical to SEQ ID NO:9 having muscle-selective promoter activity.
[0036] In certain embodiments, a nucleic acid molecule of the invention comprises, specifically from 5' to 3' in this order: - one selective liver-selective, in particular HS-CRM8 enhancer, or a functional variant or functional fragment thereof; - muscle-selective enhancers, such as MCK enhancers; and a muscle-selective promoter, in particular the spC5.12 promoter, or a functional variant or functional fragment thereof.
[0037] According to a particular variant of this embodiment, the nucleic acid molecule of the invention consists of a sequence as shown in SEQ ID NO: 10, or a functional variant thereof having a sequence at least 80% identical to SEQ ID NO: 10, for example at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or even at least 99% identical to SEQ ID NO: 10 having muscle-selective promoter activity.
[0038] In certain embodiments, a nucleic acid molecule of the invention comprises, specifically from 5' to 3' in this order: - two selective liver-selective enhancers, in particular two repeats of the HS-CRM8 enhancer or a functional variant or functional fragment thereof; and a muscle-selective promoter, in particular the spC5.12 promoter, or a functional variant or functional fragment thereof.
[0039] In certain embodiments, a nucleic acid molecule of the invention comprises, specifically from 5' to 3' in this order: - two selective liver-selective enhancers, in particular two repeats of the HS-CRM8 enhancer, or a functional variant or functional fragment thereof; - muscle-selective enhancers, such as MCK enhancers; and a muscle-selective promoter, in particular the spC5.12 promoter, or a functional variant or functional fragment thereof.
[0040] In certain embodiments, a nucleic acid molecule of the invention comprises, specifically from 5' to 3' in this order: - three selective liver-selective enhancers, in particular three repeats of the HS-CRM8 enhancer, or a functional variant or functional fragment thereof; and a muscle-selective promoter, in particular the spC5.12 promoter or a functional variant or functional fragment thereof.
[0041] According to a particular variant of this embodiment, the nucleic acid molecule of the invention consists of a sequence as shown in SEQ ID NO: 11, or a functional variant thereof having a sequence at least 80% identical to SEQ ID NO: 11, for example at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or even at least 99% identical to SEQ ID NO: 11 having muscle-selective promoter activity.
[0042] In certain embodiments, a nucleic acid molecule of the invention comprises, specifically from 5' to 3' in this order: - three selective liver-selective enhancers, in particular three repeats of the HS-CRM8 enhancer, or a functional variant or functional fragment thereof; - muscle-selective enhancers, such as MCK enhancers; and a muscle-selective promoter, in particular the spC5.12 promoter or a functional variant or functional fragment thereof.
[0043] According to a particular variant of this embodiment, the nucleic acid molecule of the invention consists of a sequence as shown in SEQ ID NO: 12, or a functional variant thereof having a sequence at least 80% identical to SEQ ID NO: 12, for example at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or even at least 99% identical to SEQ ID NO: 12 having muscle-selective promoter activity.
[0044] In all embodiments of the nucleic acid molecules of the invention specifically disclosed herein, said nucleic acid molecules may comprise a linker located between the liver-selective enhancer and the muscle-selective promoter.
[0045] Furthermore, in all embodiments of the nucleic acid molecules of the present invention specifically disclosed herein, the nucleic acid molecule may include a linker located between two liver-selective enhancers. For example, in an embodiment including two liver-selective enhancers, the linker may be located between the two liver-selective enhancers or at a position that is not between the two liver-selective enhancers. Additionally, in an embodiment including three liver-selective enhancers, a linker may be included between the first and second liver-selective enhancers and / or between the second and third liver-selective enhancers. For example, in an embodiment using three liver-selective enhancers, the linker is located between the first and second liver-selective enhancers, and no linker is located between the second and third liver-selective enhancers. In another variation, in one embodiment using three liver-selective enhancers, no linker is located between the first and second liver-selective enhancer, and a linker is located between the second liver-selective enhancer and the third liver-selective enhancer.
[0046] Expression cassette The nucleic acid molecules of the invention can be introduced into expression cassettes designed to direct expression of the transgene of interest to a tissue of interest.
[0047] Thus, an expression cassette of the present invention comprises a nucleic acid molecule as described above and a transgene of interest.
[0048] The expression cassette may also include at least one additional regulatory sequence capable of further controlling expression of the therapeutic transgene of interest by stabilizing the mRNA coding for the protein of interest, e.g., the therapeutic protein encoded by the transgene of interest, by reducing or suppressing its expression in certain tissues other than the tissue of interest. These sequences include, for example, silencers (e.g., tissue-specific silencers), microRNA target sequences, introns, and polyadenylation signals.
[0049] In certain embodiments, an expression cassette of the invention comprises, in this order from 5' to 3': - a nucleic acid molecule of the invention; - a transgene of interest; and - polyadenylation signal.
[0050] In a particular variation of this embodiment, an intron can be introduced between the nucleic acid molecule of the present invention and the transgene of interest. As a result, the intron is located between the muscle-selective promoter contained in the nucleic acid molecule described above and the transgene of interest. Alternatively, the intron can be located within the transgene of interest. In a particular embodiment, the intron can be an SV40 intron, for example, the SV40 intron consisting of SEQ ID NO: 13.
[0051] Naturally, from the teachings disclosed herein and general knowledge in the field of molecular biology and gene therapy, a person skilled in the art can select and adapt the number of enhancers, the size of the enhancers, the size of the promoter, the size of the linker, and any other elements, such as further enhancers (e.g., MCK enhancer or a functional variant thereof) and introns, according to the size of the transgene of interest incorporated in the expression cassette.
[0052] The transgene of interest may be any transgene as described in the section "Definitions" above. In addition, specific exemplary transgenes of interest are provided in the table below, in which the transgenes are rearranged by the family of neuromuscular disorders they can treat:
[0053] Muscular dystrophies
[0054] [Table 1A]
[0055] [Table 1B]
[0056] Congenital muscular dystrophies
[0057] [Table 2]
[0058] Congenital myopathies
[0059] [Table 3]
[0060] Distal myopathy
[0061] [Table 4]
[0062] Other myopathies
[0063] [Table 5]
[0064] muscle tension syndrome
[0065] [Table 6]
[0066] Ion channel muscle disease
[0067] [Table 7]
[0068] Malignant hyperthermia
[0069] [Table 8]
[0070] Metabolic myopathy
[0071] [Table 9]
[0072] Hereditary cardiac myopathies
[0073] [Table 10A]
[0074] [Table 10B]
[0075] [Table 10C]
[0076] Congenital myasthenic syndrome
[0077] [Table 11]
[0078] Motor neuron disease
[0079] [Table 12A]
[0080] [Table 12B]
[0081] Hereditary motor and sensory neuropathies
[0082] [Table 13A]
[0083] [Table 13B]
[0084] Hereditary paraplegia
[0085] [Table 14A]
[0086] [Table 14B]
[0087] Other neuromuscular disorders
[0088] [Table 15]
[0089] Vectors, cells and pharmaceutical compositions The expression cassette of the present invention can be introduced into a vector. Thus, the present invention also relates to a vector comprising the expression cassette described above. The vector used in the present invention is a vector suitable for RNA / protein expression, particularly suitable for gene therapy.
[0090] In one embodiment, the vector is a plasmid vector.
[0091] In another embodiment, the vector is a non-viral vector, such as a nanoparticle, lipid nanoparticle (LNP) or liposome, containing an expression cassette of the invention.
[0092] In another embodiment, the vector is a system based on a transposon, such as the hyperactive Sleeping Beauty (SB100X) transposon system (Mates et al., 2009), that allows integration of the expression cassette of the invention in the genome of the target cell.
[0093] In a further embodiment, the transgene of interest is a repair matrix useful for targeted genome manipulation, e.g., a repair matrix suitable for gene correction together with an endonuclease as described above. More particularly, the vector comprises a repair matrix containing arms of homology to the gene of interest for homology-driven integration.
[0094] In another embodiment, the vector is a viral vector suitable for muscle-targeted gene therapy. In this case, further sequences suitable for generating efficient viral vectors, as known in the art, are added to the expression cassette of the invention. In a particular embodiment, the viral vector is derived from an integrating virus. In particular, the viral vector may be derived from an adenovirus, a retrovirus or a lentivirus (e.g., an integration-defective lentivirus). In a particular embodiment, the lentivirus is a pseudotyped lentivirus with an envelope that allows targeting the cells / tissues of interest, such as liver and / or muscle cells (described in patent applications EP17306448.6 and EP17306447.8). When the viral vector is derived from a retrovirus or lentivirus, the further sequences are retroviral or lentiviral LTR sequences flanking the expression cassette. In another particular embodiment, the viral vector is a parvoviral vector, such as an AAV vector, such as an AAV vector suitable for muscle transduction. In this embodiment, the further sequences are AAV ITR sequences flanking the expression cassette.
[0095] In a preferred embodiment, the vector is an AAV vector.The human parvovirus adeno-associated virus (AAV) is a naturally replication-defective dependovirus that can integrate into the genome of infected cells to establish latent infection.The last property appears to be unique among mammalian viruses, since integration occurs at a specific site located on chromosome 19 (19q13.3-qter) in the human genome, called AAVS1.
[0096] AAV vectors have therefore attracted considerable interest as potential vectors for human gene therapy. Among the favorable properties of the virus are its lack of association with any human disease, its ability to infect both dividing and non-dividing cells, and the wide range of cell lines derived from different tissues that can be infected.
[0097] Among the AAV serotypes isolated and well characterized from humans or non-human primates (NHPs), human serotype 2 was the first AAV to be developed as a gene transfer vector. Other AAV serotypes currently in use include AAV-1, AAV-2 variants (e.g., quadruple mutant capsid-optimized AAV-2, comprising an engineered capsid with Y44+500+730F+T491V changes, as disclosed in Ling et al., 2016, July 18, Hum Gene Ther Methods.), -3 and AAV-3 variants (e.g., AAV3-ST variant, comprising an engineered AAV3 capsid with two amino acid changes, S663V+T492V, as disclosed in Vercauteren et al., 2016, Mol. Ther., 24(6), 1042), -3B and AAV-3B variants, -4, -5, -6 and AAV-6 variants (e.g., Rosario et al., 2016, Mol Ther Methods Clin Dev. 3, p. 16026), -7, -8, -9, -2G9, -10, e.g., cy10 and -rh10, -rh74, -rh74-9, etc., as disclosed in EP18305399 (e.g., Hybrid Cap rh74-9 serotype as described in the Examples of EP18305399; rh74-9 serotype is also referred to herein as "-rh74-9", "AAVrh74-9" or "AAV-rh74-9"); -9-rh74 as disclosed in EP18305399 (e.g., Hybrid Cap AAVs include the 9-rh74 serotype (-9-rh74 serotype is also referred to herein as "-9-rh74", "AAV9-rh74", "AAV-9-rh74", or "rh74-AAV9"), -dj, Anc80, LK03, AAV2i8, porcine AAV serotypes, such as AAVpo4 and AAVpo6, as well as tyrosine, lysine and serine capsid mutants of AAV serotypes, etc. In addition, other non-naturally occurring, engineered mutants and chimeric AAVs may also be useful.
[0098] AAV viruses can be engineered using conventional molecular biology techniques, allowing these particles to be optimized for cell-specific delivery of nucleic acid sequences, for minimizing immunogenicity, for tailoring stability and particle longevity, for efficient degradation, and for precise delivery to the nucleus.
[0099] Desirable AAV fragments for assembly into vectors include the cap proteins, including vp1, vp2, vp3 and hypervariable regions, the rep proteins, including rep78, rep68, rep52, and rep40, and sequences encoding these proteins. These fragments can be readily utilized in a variety of vector systems and host cells.
[0100] AAV-based recombinant vectors that lack Rep proteins integrate into the host genome with low efficiency and exist primarily as stable circular episomes that can persist for several years in target cells.
[0101] Instead of using AAV natural serotypes, in the context of the present invention, artificial AAV serotypes can be used, including, without limitation, AAVs with non-naturally occurring capsid proteins. Such artificial capsids can be generated by any suitable technique using selected AAV sequences (e.g., fragments of vp1 capsid protein) in combination with heterologous sequences that can be obtained from different selected AAV serotypes, non-contiguous parts of the same AAV serotype, non-AAV viral sources, or non-viral sources. The artificial AAV serotypes can be, without limitation, chimeric AAV capsids, recombinant AAV capsids, or "humanized" AAV capsids.
[0102] In the context of the present invention, an AAV vector comprises an AAV capsid capable of transducing a target cell of interest, i.e. a muscle cell.
[0103] According to certain embodiments, the AAV vector is an AAV-1, -2, AAV-2 variant (e.g., quadruple mutant capsid-optimized AAV-2 comprising an engineered capsid with Y44+500+730F+T491V changes as disclosed in Ling et al., 2016 July 18, Hum Gene Ther Methods. [Epub ahead of print]), -3 and AAV-3 variant (e.g., AAV3-ST variant comprising an engineered AAV3 capsid with two amino acid changes, S663V+T492V as disclosed in Vercauteren et al., 2016, Mol. Ther., 24(6), 1042), -3B and AAV-3B variant, -4, -5, -6 and AAV-6 variant (e.g., Rosario et al., 2016, Mol. Ther. Methods Clin. 2016, 11, 1131-1135, 1999). Dev. 3, p. 16026), -7, -8, -9, -2G9, -10, e.g., -cy10 and -rh10, -rh39, -rh43, -rh74, -rh74-9, -dj, Anc80, LK03, AAV.PHP, AAV2i8, porcine AAV, e.g., AAVpo4 and AAVpo6, and vectors of tyrosine, lysine and serine capsid mutants of AAV serotypes. In certain embodiments, the AAV vector is a vector of AAV8, AAV9, AAVrh74, AAVrh74-9, or AAV2i8 serotype (i.e., the AAV vector has a capsid of AAV8, AAV9, AAVrh74, AAVrh74-9, or AAV2i8 serotype). In further specific embodiments, the AAV vector is a pseudotyped vector, i.e., its genome and capsid are derived from different serotypes of AAV. For example, a pseudotyped AAV vector may be a vector whose genome is derived from one of the above-mentioned AAV serotypes and whose capsid is derived from another serotype. For example, the genome of the pseudotyped vector may have a capsid derived from AAV8, AAV9, AAVrh74, AAVrh74-9, or AAV2i8 serotype, and its genome may be derived from a different serotype.In certain embodiments, the AAV vector has a capsid of the AAV8, AAV9, AAVrh74 or AAVrh74-9 serotype, particularly a capsid of the AAV8 or AAV9 serotype, more particularly a capsid of the AAV8 serotype.
[0104] In another embodiment, the capsid is a modified capsid. In the context of the present invention, a "modified capsid" may be a chimeric capsid or a capsid comprising one or more mutant VP capsid proteins derived from one or more wild-type AAV VP capsid proteins.
[0105] In certain embodiments, the AAV vector is a chimeric vector, i.e., its capsid comprises VP capsid proteins derived from at least two different AAV serotypes, or comprises at least one chimeric VP protein that combines VP protein regions or domains derived from at least two AAV serotypes. For example, a chimeric AAV vector can be derived from a combination of an AAV8 capsid sequence and a set of AAV serotypes different from the AAV8 serotype, such as any of those specifically mentioned above.
[0106] In another embodiment, modified capsids can also be derived from capsid modifications inserted by error-prone PCR and / or peptide insertion (e.g., as described in Bartel et al., 2011). In addition, capsid mutants can include single amino acid changes, such as tyrosine mutations (e.g., as described in Zhong et al., 2008).
[0107] In addition, the genome of the AAV vector can be either single-stranded or self-complementary double-stranded genome (McCarty et al., Gene Therapy, 2003). Self-complementary double-stranded AAV vectors are generated by deleting the terminal release site from one of the AAV terminal repeats. These modified vectors, whose replicative genomes are half the length of the wild-type AAV genome, tend to package DNA dimers. In a preferred embodiment, the AAV vector introduced into the practice of the present invention has a single-stranded genome, and more preferably comprises an AAV8, AAV9, AAVrh74, AAVrh74-9, or AAV2i8 capsid, particularly an AAV8, AAV9, AAVrh74, or AAVrh74-9 capsid, such as an AAV8 or AAV9 capsid, more particularly an AAV8 capsid. As known in the art, additional appropriate sequences can be introduced into the nucleic acid construct of the present invention to obtain a functional viral vector. Suitable sequences include the AAV ITRs.
[0108] Of course, in designing the nucleic acid sequence of the present invention and the expression cassette of the present invention, the skilled artisan will take into consideration the size limit of the vector used to deliver said construct to a cell or organ. In particular, as noted above, when the vector is an AAV vector, the skilled artisan will be aware that the main limitation of an AAV vector is its payload capacity, which may vary with each AAV serotype, but which is considered to be limited to the vicinity of the size of the parental viral genome. For example, 5 kb is the maximum size that is considered to be normally packaged in an AAV8 capsid. (Wu Z. et al., Mol Ther., 2010, Vol. 18(1): 80-86; Lai Y. et al., Mol Ther., 2010, Vol. 18(1): 75-79; Wang Y. et al., Hum Gene Ther Methods, 2012, Vol. 23(4): 225-33). Thus, in practicing the invention, the skilled artisan will be mindful to select the components of the nucleic acid construct of the invention such that the resulting nucleic acid sequence, including sequences encoding the AAV 5'- and 3'-ITRs, preferably does not exceed 110% of the payload capacity of the AAV vector into which it is introduced, and particularly preferably does not exceed 5.5 kb.
[0109] The present invention also relates to isolated cells, e.g. muscle cells, transformed with the nucleic acid sequence of the present invention or the expression cassette of the present invention. The cells of the present invention can be delivered to a subject in need thereof via injection into the tissue of interest or into the bloodstream of said subject. In a particular embodiment, the present invention comprises the step of introducing the nucleic acid molecule or expression cassette of the present invention into the cells of the subject to be treated and returning said cells into which the nucleic acid or expression cassette has been introduced to this subject.
[0110] The present invention also provides pharmaceutical compositions comprising the nucleic acid molecules, vectors or cells of the present invention. Such compositions comprise a therapeutically effective amount of the nucleic acid sequences, vectors or cells of the present invention and a pharmaceutically acceptable carrier. The term "pharmaceutically acceptable" means approved by a regulatory federal agency or state government, or listed in the United States or European Pharmacopoeia or other generally recognized pharmacopoeias for use in animals and humans. The term "carrier" refers to a diluent, adjuvant, excipient, or vehicle with which the therapeutic is administered. Such pharmaceutical carriers are sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, for example, peanut oil, soybean oil, mineral oil, sesame oil, and the like. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene glycol, water, ethanol, and the like.
[0111] The compositions may also contain minor amounts of wetting or emulsifying agents, or pH buffering agents, if desired. These compositions may take the form of solutions, suspensions, emulsions, tablets, pills, capsules, powders, sustained release formulations, and the like. Oral formulations may include standard carriers, such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, cellulose, magnesium carbonate, and the like. Examples of suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by EW Martin. Such compositions will contain a therapeutically effective amount of the therapeutic agent, preferably in purified form, together with a suitable amount of carrier to provide the form for proper administration to a subject. In certain embodiments, the nucleic acid sequences, expression cassettes, vectors, or cells of the invention are formulated in a composition comprising phosphate buffered saline and supplemented with 0.25% human serum albumin. In another particular embodiment, the vector of the invention is formulated in a composition comprising Ringer's lactate and a non-ionic surfactant, such as Pluronic® F68, at a final concentration of 0.01-0.0001% by weight of the total composition, for example at a concentration of 0.001% by weight. The formulation may further comprise serum albumin, in particular human serum albumin, for example human serum albumin at 0.25%. Other suitable formulations for either storage or administration are known in the art, in particular from WO2005 / 118792 or Allay et al., 2011.
[0112] In a preferred embodiment, the composition is formulated according to a routine procedure as a pharmaceutical composition adapted for intravenous or intramuscular administration to humans, preferably intravenous administration.Usually, compositions for intravenous administration are solutions in sterile isotonic aqueous buffer.If necessary, the composition may also include a solubilizing agent and a local anesthetic, such as lignocaine, to ease pain at the injection site.
[0113] In one embodiment, the nucleic acid sequence, expression cassette or vector of the invention can be delivered in a vesicle, in particular a liposome, hi yet another embodiment, the nucleic acid sequence, expression cassette or vector of the invention can be delivered in a controlled release system.
[0114] How to use vectors Thanks to the present invention, a transgene of interest can be expressed in muscle or muscle cells.
[0115] The nucleic acid molecules, expression cassettes or vectors of the invention can be used to express a gene in a muscle cell. Thus, the invention provides a method for expressing a transgene of interest in a muscle cell, wherein an expression cassette of the invention is introduced into the muscle cell and the transgene of interest is expressed. The method may be an in vitro, ex vivo or in vivo method for expressing a transgene of interest in a muscle cell.
[0116] The nucleic acid molecule, expression cassette or vector of the present invention can also be used for gene therapy.Thus, in one aspect, the present invention relates to a nucleic acid molecule, expression cassette, vector, cell or pharmaceutical composition as described above for use as a medicament.Thus, in one aspect, the present invention relates to a nucleic acid molecule, expression cassette or vector disclosed herein for use in therapy, particularly gene therapy.Similarly, the cell of the present invention can be used in therapy, particularly cell therapy.
[0117] In another aspect, the invention relates to a nucleic acid molecule, an expression cassette, a vector, a cell or a pharmaceutical composition as described above for use in a method for treating a neuromuscular disorder.
[0118] In a further aspect, the invention relates to the use of a nucleic acid molecule, an expression cassette, a vector, a cell or a pharmaceutical composition as described above for the manufacture of a medicament for use in the treatment of a neuromuscular disorder.
[0119] In another aspect, the invention relates to a method for the treatment of a neuromuscular disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a nucleic acid molecule, expression cassette, vector, cell or pharmaceutical composition as described herein.
[0120] The neuromuscular disorder is in particular an inherited or acquired disorder, such as an inherited or acquired neuromuscular disease. Naturally, the therapeutic transgene and promoter driving expression to the tissue of therapeutic interest will be selected having regard to the disorder to be treated.
[0121] The term "neuromuscular disorder" encompasses diseases and conditions that impair muscle function, either directly (pathology of voluntary muscles) or indirectly (pathology of nerves or the neuromuscular junction). Exemplary neuromuscular disorders include, without limitation, muscular dystrophies (e.g., myotonic dystrophy (Steiner's disease), Duchenne muscular dystrophy, Becker muscular dystrophy, limb-girdle muscular dystrophy, facioscapulohumeral muscular dystrophy, congenital muscular dystrophy, oculopharyngeal muscular dystrophy, distal muscular dystrophy, Emery-Drefuss muscular dystrophy), motor neuron diseases (e.g., amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (infantile progressive spinal muscular atrophy (type 1, Werdnig-Holmes disease), and spinal muscular atrophy (infantile progressive spinal muscular atrophy (type 1, Werdnig-Holmes disease), ... Fumann's disease), intermediate spinal muscular atrophy (type 2), juvenile spinal muscular atrophy (type 3, Kugelberg-Welander disease), adult spinal muscular atrophy (type 4), spinal-bulbar muscular atrophy (Kennedy's disease), inflammatory myopathies (e.g., polymyositis, dermatomyositis, inclusion body myositis), diseases of the neuromuscular junction (e.g., myasthenia gravis, Lambert-Eaton (myasthenic) syndrome, congenital myasthenic syndromes), diseases of the peripheral nerves (e.g., Charcot-Marie-Tooth disease, Friedreich's ataxia, Dejerine-Sottas disease), metabolic diseases of muscle (e.g., Phosphorylase deficiency (McArdle disease), acid maltase deficiency (Pompe disease), phosphofructokinase deficiency (Tarui disease), debranching enzyme deficiency (Cori disease or Forbes disease), mitochondrial myopathy, carnitine deficiency, carnitine palmityltransferase deficiency, phosphoglycerate kinase deficiency, phosphoglycerate mutase deficiency, lactate dehydrogenase deficiency, myoadenylate deaminase deficiency), myopathy due to endocrine abnormalities (e.g., hyperthyroid myopathy, thyroid function myopathy, myotonia congenita, myotonia congenita, myotubular myopathy, periodic paralysis. In this embodiment, the nucleic acid sequences of the invention include liver-selective, muscle-selective and / or neuron-selective transcriptional regulatory elements, e.g., liver-selective and muscle-selective transcriptional regulatory elements, liver-selective and neuron-selective transcriptional regulatory elements, and liver-selective, muscle-selective and neuron-selective transcriptional regulatory elements.
[0122] In a particular embodiment, the disorder is a glycogen storage disease. The term "glycogen storage disease" refers to a group of inherited metabolic disorders involving the enzymes responsible for the synthesis and degradation of glycogen. In a more particular embodiment, the glycogen storage disease may be GSDI (von Gierke's disease), GSDII (Pompe's disease), GSDIII (Cori's disease), GSDIV, GSDV, GSDVI, GSDVII, GSDVIII or fatal congenital glycogen storage disease of the heart. More particularly, the glycogen storage disease is selected in the group consisting of GSDI, GSDII and GSDIII, even more particularly in the group consisting of GSDII and GSDIII. In an even more particular embodiment, the glycogen storage disease is GSDII. In particular, the nucleic acid molecules of the invention may be useful in gene therapy for treating GAA deficiency conditions or other conditions associated with glycogen accumulation, such as GSDI (von Gierke's disease), GSDII (Pompe's disease), GSDIII (Cori's disease), GSDIV, GSDV, GSDVI, GSDVII, GSDVIII and fatal congenital glycogen storage disease of the heart, more particularly GSDI, GSDII or GSDIII, even more particularly GSDII and GSDIII. In a further particular embodiment, the disorder is Pompe's disease and the therapeutic transgene is a gene encoding acid alpha-glucosidase (GAA) or a variant thereof. Such variants of GAA are disclosed in particular in applications PCT / 2017 / 072942, PCT / EP2017 / 072945 and PCT / EP2017 / 072944, which are hereby incorporated by reference in their entirety. In this embodiment, the nucleic acid sequence of the present invention comprises a liver-selective, muscle-selective and / or neuron-selective transcriptional regulatory element, such as a liver-selective and muscle-selective transcriptional regulatory element, a liver-selective and neuron-selective transcriptional regulatory element, a muscle-selective and neuron-selective transcriptional regulatory element, and a liver-selective, muscle-selective and neuron-selective transcriptional regulatory element. In a particular embodiment, the disorder is infantile-onset Pompe disease (IOPD) or late-onset Pompe disease (LOPD). Preferably, the disorder is IOPD.
[0123] Those skilled in the art are aware of transgenes of interest that are useful for the treatment of these and other disorders by gene therapy. For example, therapeutic transgenes are lysosomal enzyme alpha-L-iduronidase [IDUA (alpha-L-iduronidase)] for MPS I, acid-alpha-glucosidase (GAA) for Pompe disease, glycogen debranching enzyme (GDE) or truncated forms of GDE (also called truncated forms of GDE or small GDE) for Cori disease (GSDIII), G6P for GSDI, alpha-sarcoglycan (SGCA) for LGMD2D, dystrophin or truncated forms thereof for DMD, and SMN1 for SMA. Transgenes of interest may also be transgenes that provide other therapeutic properties than providing a missing protein or RNA that suppresses the expression of a given protein. For example, transgenes of interest may include, without limitation, transgenes that can increase muscle strength.
[0124] Specific examples of therapeutic transgenes of interest that can be operably linked to the hybrid promoters of the present invention for specific diseases are provided below.
[0125] In a particular embodiment, the disease is coli disease and the transgene of interest encodes a GDE or a truncated form of a GDE. A truncated form of a GDE suitable for use in the present invention may include, without limitation, those described in EP18306088. Alternatively, the present invention is used in a double AAV vector system for expressing a GDE, for example the double AAV vector system disclosed in WO2018162748. In this embodiment, the vector of the present invention may correspond to the first AAV vector of the double AAV vector system comprising the AAV ITR between 5' and 3', i.e. the first nucleic acid sequence encoding the N-terminal portion of the GDE, under the control of the nucleic acid molecule of the present invention.
[0126] In another specific embodiment, the disease is Pompe disease and the transgene of interest encodes acid-alpha-glucosidase (GAA), or modified GAA. Modified GDEs suitable for use in the present invention include, without limitation, those disclosed in WO2018046772, WO2018046774, and WO2018046775.
[0127] In further particular embodiments, the disorder is selected from Duchenne muscular dystrophy, myotubular myopathy, spinal muscular atrophy, limb-girdle muscular dystrophy types 2I, 2A, 2B, 2C or 2D and myotonic dystrophy type 1.
[0128] Methods of administration of the vectors of the present invention include, but are not limited to, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, local area administration, and oral routes as described in WO2015158924. In certain embodiments, administration is via intravenous or intramuscular routes. The vectors of the present invention can be administered by any convenient route, such as by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.), and can be administered together with other biologically active substances. Administration can be systemic or local.
[0129] In certain embodiments, it may be desirable to administer the pharmaceutical compositions of the present invention locally to the area requiring treatment, e.g., liver or muscle. This can be accomplished, for example, by means of an implant, which may be a porous, non-porous, or gelatinous material, including membranes, such as sialastic membranes, or fibers.
[0130] The amount of the vector of the invention that is effective in treating the disorder to be treated can be determined by standard clinical techniques. In addition, in vivo and / or in vitro assays can be optionally used to help predict optimal dosage ranges. The exact dose to be employed in the formulation will also depend on the route of administration, and the severity of the disease, and should be determined according to the judgment of the physician and each patient's circumstances. The dose of the vector of the invention administered to a subject in need thereof will vary based on several factors, including, without limitation, the route of administration, the particular disease being treated, the age of the subject, or the level of expression required to obtain a therapeutic effect. One of skill in the art can readily determine the required dosage range based on these factors and others, based on his or her knowledge in the art. For treatments involving administration of an AAV vector to a subject, a typical dose of the vector is at least 1×10 per kilogram of body weight. 8 of vector genome (vg / kg), e.g., at least 1 × 10 9 vg / kg, at least 1 × 10 10 vg / kg, at least 1 × 10 11 vg / kg, at least 1 × 10 12 vg / kg, at least 1 × 10 13 vg / kg, at least 1 × 10 14 vg / kg or at least 1 × 10 15 vg / kg.
[0131] In certain embodiments, the vector of the present invention may be administered at a lower dose than the typical dose used in gene therapy.In particular, in the treatment comprising administering an AAV vector to a subject in need thereof, the vector may be administered at a dose of 2 times less than the typical dose described above, in particular at a dose of 3 times less, 4 times less, 5 times less, 6 times less, 7 times less, 8 times less, 9 times less, 10 times less, 11 times less, 12 times less, 13 times less, 14 times less, 15 times less, 16 times less, 17 times less, 18 times less, 19 times less, 20 times less, 21 times less, 22 times less, or less than 23 times lower, or less than 24 times lower, or less than 25 times lower, or less than 26 times lower, or less than 27 times lower, or less than 28 times lower, or less than 29 times lower, or less than 30 times lower, or less than 31 times lower, or less than 32 times lower, or less than 33 times lower, or less than 34 times lower, or less than 35 times lower, or less than 36 times lower, or less than 37 times lower, or less than 38 times lower, or less than 39 times lower, or less than 40 times lower, or less than 41 times lower, or less than 42 times lower, or less than 43 times lower, or less than 44 times lower, or less than 45 times lower, or less than 46 times lower, or less than 47 times lower, or less than 48 times lower, or less than 49 times lower, or even at least 50 times lower. EXAMPLES
[0132] Materials and Methods In vivo experiments All mouse experiments were performed in accordance with French and European legislation on animal care and experimentation (2010 / 63 / EU) and approved by the local institutional ethical committee (protocol no. 2016-002B). AAV vectors were administered intravenously via the tail vein of 6-8 week old male C57Bl6 / J mice. PBS-injected littermates were used as controls. At sacrifice, mice were perfused with PBS to avoid blood contamination in tissues. After sampling, tissues were homogenized in DNAse / RNAse-free water using Fastprep tubes (4 m / s; 60 s).
[0133] mSeAP activity mSeAP activity in tissues was measured using the Phospha-Light™ SEAP Reporter Gene Assay System (ThermoFisher) according to the manufacturer's instructions.
[0134] Plasmid construction. Enhancer / promoter (EP) sequences were purchased from commercial sources. mSeAP cDNA was ligated to each EP sequence using XhoI and Mlu1 restriction enzymes. The resulting transgene expression cassette was cloned between two ITRs derived from AAV2 using XbaI restriction enzyme recognition sites flanking the sequence.
[0135] A description of the promoter / enhancer combinations generated and used in the experimental section is shown in Table 1 below.
[0136] [Table 16]
[0137] result As reported in Figure 1, tissue-specific expression driven by four combinations of enhancer and promoter were evaluated. These promoters consisted of a muscle-specific promoter (spC5-12) combined with the muscle enhancer MCK (MCK-spC5-12, Table 1). This combination of promoter and enhancer was known in the literature (Wang B., Gene therapy, 2008) as E-Syn. Novel hybrid promoters were obtained by fusing one (H1) or three repeats (H3) of the liver enhancer HS-CRM8 at position 1 of the MCK-spC5-12 promoter / enhancer combination (H1-MCK-spC5-12 and H3-MCK-spC5-12, respectively, Table 1). To verify the tissue specificity of these constructs, the mouse secreted alkaline phosphatase (mSeAP) reporter gene was used. Transgene expression cassettes carrying this reporter gene and four promoter / enhancer combinations were pseudotyped into AAV9 vectors generated by triple transfection and cesium chloride gradient purification.
[0138] The mSeAP-AAV9 vector was injected into 2-month-old C57Bl6 / J male mice at 2 × 10 11Mice were intravenously injected with a dose of vector genome of 1000 mg / kg / day. In parallel, mice were injected with phosphate buffered saline (PBS) as a control. One month after vector injection, the animals were sacrificed. Mice were perfused with PBS to avoid blood contamination in the tissues. Muscle and non-muscle tissues were biochemically analyzed to quantify mSEAP enzymatic activity. In muscle, the spC5-12 promoter or the MCK-spC5-12 enhancer / promoter did not result in significant and detectable mSEAP activity compared to PBS-injected mice (Figure 2). Interestingly, AAV9 expressing mSEAP under the transcriptional control of the H1-MCK-spC5-12 and H3-MCK-spC5-12 hybrid promoters allowed a significant, 5- to 10-fold increase in mSEAP activity in different skeletal muscles (Figure 2). In the diaphragm and posterior tibial muscles, we observed a higher increase in mSEAP activity of 150 and 20 fold, respectively, for the H3-MCK-spC5-12 enhancer / promoter. In the liver, we did not observe any significant increase in mSEAP expression (Figure 3). In the kidney and brain, we observed a significant 2-3 fold increase in mSEAP expression in mice given vectors carrying H1-MCK-spC5-12 and H3-MCK-spC5-12 (Figure 3).
[0139] Considering that there was higher mSEAP expression in muscle compared to other tissues, these data demonstrate that fusion of one or three copies of HS-CRM8 at the 5' of the synthetic muscle promoter (MCK-spC5-12) specifically increases transgene expression in muscle, thus providing a novel tool for gene therapy for neuromuscular disorders.
[0140] The size of the promoter was then reduced by removing the MCK enhancer. AAV9 vectors expressing mSEAP under the transcriptional control of (i) the spC5-12 promoter, (ii) the spC5-12 promoter directly fused with three copies of HS-CRM8 (H3-spC5-12), or (iii) the H3-MCK-spC5-12 hybrid promoter were prepared. The mSeAP-AAV9 vector was injected into C57Bl / 6 male mice at 4 × 10 per mouse. 11 The mice were injected with a dose of vector genome of 0.01 mg / kg / day. In parallel, mice were injected with phosphate buffered saline (PBS) as a control. One month after vector injection, the animals were sacrificed. Mice were perfused with PBS to avoid blood contamination in the tissues. Muscle tissue was analyzed to quantify mSeAP enzyme activity. Importantly, in muscle, unlike the spC5-12 promoter, fusion of the spC5-12 promoter with H3 or H3-MCK resulted in significant and detectable mSEAP activity compared to PBS-injected mice (Figure 4). These data suggest that the increased muscle expression of the transgene is not dependent on the presence of the MCK enhancer. The following transgene expression cassette constructs do not contain this enhancer:
[0141] To confirm the reliability of the observed effects when fusing the H3 enhancer to muscle promoters, two novel promoter / enhancer combinations involving the CK6 and CK8 promoters, which are frequently used in in-vivo gene therapy, were created. AAV9 vectors expressing mSEAP under the transcriptional control of the CK6 or CK8 promoter, or under the control of CK6 or CK8 directly fused to three copies of HS-CRM8 (H3-CK6 and H3-CK8, respectively) were prepared. The mSeAP-AAV9 vectors were injected into C57Bl / 6 male mice at 5 × 10 per mouse. 11The animals were sacrificed 15 days after vector injection. Mice were perfused with PBS to avoid blood contamination in the tissues. Muscle tissue was analyzed to quantify mSeAP enzyme activity. Importantly, in muscle, fusion of H3 with both muscle-specific promoters, CK6 and CK8, resulted in significant and detectable mSEAP activity compared to the parental CK6 and CK8 promoters, respectively (Figure 5). Similar findings were reported for different promoters, i.e., ACTA1 fused with three copies of HS-CRM8 (H3-ACTA1) resulted in a similar level of mSEAP transgene expression in muscle to that measured by the H3-spC5-12 hybrid promoter (Figure 6). Of note, in a different experimental setting, the ACTA1 promoter showed comparable efficacy to the spC5-12 promoter in muscle (data not shown). These data suggest that H3 induces an increase in promoter efficacy regardless of the muscle-selective promoter.
[0142] Finally, to confirm that other liver-selective enhancers have a similar effect, we tested the regulatory sequence controlling the transcription of fibrinogen alpha chain fused to the spC5-12 promoter (F-spC5-12) (described as HS-CRM11 in Chuah et al., Molecule Therapy, 2014, vol. 22, no. 9, p. 1605). The F-spC5-12 hybrid promoter resulted in a significant increase in mSEAP transgene expression when compared to the spC5-12 promoter (Figure 7), thus demonstrating that, like H3, other liver-specific enhancers increase transgene expression driven by muscle-specific promoters in muscle.
Claims
1. A nucleic acid molecule comprising one or more liver-selective enhancers operably linked to a muscle-selective promoter, - the liver-selective enhancer comprises or consists of a sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32 and SEQ ID NO:33, a functional variant having 80% identity to any one of the sequences selected from SEQ ID NO:1, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32 and SEQ ID NO:33, and a functional fragment thereof; or - a nucleic acid molecule, wherein the plurality of liver-selective enhancers comprises at least one liver-selective enhancer comprising or consisting of a sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32 and SEQ ID NO:33, a functional variant having 80% identity to any one of the sequences selected from SEQ ID NO:1, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32 and SEQ ID NO:33, and functional fragments thereof.
2. The nucleic acid molecule of claim 1, wherein all of the liver-selective enhancers of the multiple liver-selective enhancers have the same sequence.
3. The nucleic acid molecule of claim 1, wherein at least two of the liver-selective enhancers have different sequences.
4. 4. The nucleic acid molecule of claim 1, wherein the multiple liver-selective enhancers include at least two liver-selective enhancers.
5. 5. The nucleic acid molecule of claim 1, wherein the multiple liver-selective enhancers include three liver-selective enhancers.
6. A nucleic acid molecule according to any one of claims 1 to 5, wherein the sequence of the liver-selective enhancer consists of SEQ ID NO: 1 or is a functional variant having a sequence at least 80% identical to SEQ ID NO:
1.
7. 6. A nucleic acid molecule according to any one of claims 1 to 5, wherein the sequence of the liver-selective enhancer consists of SEQ ID NO: 30 or is a functional variant having a sequence at least 80% identical to SEQ ID NO:
30.
8. 8. The nucleic acid molecule according to any one of claims 1 to 7, wherein the promoter is an spC5-12 promoter, in particular the spC5-12 promoter consists of the sequence shown in SEQ ID NO: 2, 3 or 4, or is a functional variant having a sequence at least 80% identical to SEQ ID NO: 2, 3 or 4.
9. 8. The nucleic acid molecule according to any one of claims 1 to 7, wherein the promoter is a CK6 promoter, in particular the CK6 promoter consists of the sequence shown in SEQ ID NO: 6 or is a functional variant having a sequence at least 80% identical to SEQ ID NO:
6.
10. 8. The nucleic acid molecule according to any one of claims 1 to 7, wherein the promoter is a CK8 promoter, in particular the CK8 promoter consists of the sequence shown in SEQ ID NO: 7 or is a functional variant having a sequence at least 80% identical to SEQ ID NO:
7.
11. A nucleic acid molecule according to any one of claims 1 to 7, wherein the promoter is the ACTA1 promoter, in particular the ACTA1 promoter consists of the sequence shown in SEQ ID NO: 8 or is a functional variant having a sequence at least 80% identical to SEQ ID NO:
8.
12. 12. The nucleic acid molecule of claim 1, further comprising a liver-selective enhancer or a muscle-selective enhancer located between the liver-selective enhancer or enhancers and the muscle-selective promoter.
13. 12. An expression cassette comprising a nucleic acid molecule according to any one of claims 1 to 11 operably linked to a transgene of interest.
14. A vector comprising an expression cassette according to claim 13, in particular a plasmid or viral vector.
15. The vector of claim 14, wherein the viral vector is an adeno-associated viral (AAV) vector.
16. 14. An isolated recombinant cell comprising the expression cassette of claim 13.
17. 17. An expression cassette as claimed in claim 13, a vector as claimed in claim 14 or 15, or a cell as claimed in claim 16, for use as a medicament.
18. 17. An expression cassette as claimed in claim 13, a vector as claimed in claim 14 or 15, or a cell as claimed in claim 16, for use in the treatment of a neuromuscular disorder.
19. Neuromuscular disorders include muscular dystrophies (e.g., myotonic dystrophy (Steiner's disease), Duchenne muscular dystrophy, Becker muscular dystrophy, limb-girdle muscular dystrophy, facioscapulohumeral muscular dystrophy, congenital muscular dystrophy, oculopharyngeal muscular dystrophy, distal muscular dystrophy, Emery-Dreifuss muscular dystrophy, motor neuron diseases (e.g., amyotrophic lateral sclerosis (ALS)), spinal muscular atrophies (infantile progressive spinal muscular atrophy (type 1, Wehman's disease), Rudnig-Hoffmann disease), intermediate spinal muscular atrophy (type 2), juvenile spinal muscular atrophy (type 3, Kugelberg-Welander disease), adult spinal muscular atrophy (type 4), spinal-bulbar muscular atrophy (Kennedy disease), inflammatory myopathies (e.g., polymyositis, dermatomyositis, inclusion body myositis), diseases of the neuromuscular junction (e.g., myasthenia gravis, Lambert-Eaton (myasthenic) syndrome, congenital myasthenic syndromes), diseases of the peripheral nerves (e.g., Charcot-Marie-Tooth disease, Friedreich's ataxia) metabolic disorders of muscle (e.g., phosphorylase deficiency (McArdle disease), acid maltase deficiency (Pompe disease), phosphofructokinase deficiency (Tarui disease), debranching enzyme deficiency (Cori disease or Forbes disease), mitochondrial myopathy, carnitine deficiency, carnitine palmityltransferase deficiency, phosphoglycerate kinase deficiency, phosphoglycerate mutase deficiency, lactate dehydrogenase deficiency, myoadenylate myopathy, 18. The expression cassette of claim 13, the vector of claim 14 or the cell of claim 16, for use according to claim 18, wherein the myopathy is selected from the group consisting of myotonia congenita, myotonia congenita, central core myopathy, nemaline myopathy, myotubular myopathy, periodic paralysis.
Citation Information
Patent Citations
Screening of utrophin gene expression enhancer
JP2007319073A
Systemic synthesis and regulation of L-DOPA
JP2018522595A
Methods of packaging multiple adeno-associated virus vectors
WO2015196179A1
Composite material comprising a polyurethane-polyacrylate resin matrix
WO2019053061A1
EP17306447.8
